Dr. Carlos Alonso-Moreno
Unidad NanoCRIB, Centro Regional de Investigaciones Biomédicas, Albacete-02008, Spain.
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
36Years (1991-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications14 March 2014 in Chemical Society Reviews
Journal Article
Carlos Alonso-MorenoAAAntonio Antiñolo
Antonio AntiñoloFHFERNANDO CARRILLO HERMOSILLA
FERNANDO CARRILLO HERMOSILLAAOAntonio Otero
Antonio OteroThis review focuses on the metal-mediated catalytic addition of amines to carbodiimides as an atom-economical alternative to the classical synthesis of guanidines.
Journal Article
AJAlberto Juan
Alberto JuanFCFrancisco J. Cimas
Francisco J. Cimas
Iván BravoAPAtanasio Pandiella
Atanasio PandiellaAOAlberto Ocana
Alberto OcanaCarlos Alonso-MorenoNanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.
25 October 2007 in Organometallics
Journal Article
Luis Fernando Sánchez-Barba Merlo
Andrés Garcés OsadoMFMariano Fajardo
Mariano FajardoCarlos Alonso-MorenoJFJuan Fernández-Baeza
Juan Fernández-Baeza
MLMaría I. López-Solera
María I. López-Solera +4
1 June 2015 in Chemistry – A European Journal
Journal Article
Javier MartinezJCJosé A. Castro-Osma
José A. Castro-OsmaAEAmy Earlam
Amy Earlam
Carlos Alonso-MorenoAOAntonio Otero
Antonio Otero
Antonio Rodriguez-Dieguez +2
Journal Article
AJAlberto Juan
Alberto JuanFCFrancisco J. Cimas
Francisco J. CimasIván BravoAPAtanasio Pandiella
Atanasio PandiellaAOAlberto Ocana
Alberto OcanaCarlos Alonso-MorenoBreast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.
27 May 2010 in Organometallics
Journal Article
Carlos Alonso-MorenoFHFERNANDO CARRILLO HERMOSILLA
FERNANDO CARRILLO HERMOSILLAAndrés Garcés OsadoAOAntonio Otero
Antonio OteroILIsabel López-Solera
Isabel López-SoleraAAAntonio Antiñolo
Antonio Antiñolo +1
About Me
Carlos Alonso-Moreno was born in 1978 outside Ciudad Real, Spain. In 2000, he earned his Bachelor of Science in Chemistry from the University of Castilla-La Mancha. During that time, he conducted undergraduate research with Professor Antonio Otero studying metallocene chemistry. Alonso-Moreno earned his Ph.D. with Professor Antonio Antiñolo at University of Castilla-La Mancha in 2005 for his dissertation on metallocene catalyzed olefin polymerization. After a two-year postdoctoral appointment with Professor Manfred Bochmann at the School of Pharmacy in the University of East-Anglia, United Kingdom, and a short brief of one-year at the University of Rey Juan Carlos, Spain, Alonso-Moreno began his independent career at University of Castilla-La Mancha in 2008. In 2010, he was promoted to Associate Professor and in 2018 was named Professor of Inorganic Chemistry at the School of Pharmacy in the University of Castilla-La Mancha, Spain, in which he was Vice-dean (2012–2017). His research has been mainly involved in the design and development of new organometallic entities as efficient catalysis to produce biodegradable polymers. Today, he is mainly interested in the application of the tailor-made polymeric macrostructures in oncology by the generation of nanodevices. Dr. Alonso Morneo has authored more than 50 papers on peer review journals. His h-index in Scopus is 23.